Camrelizumab and Apatinib Plus GP
Phase 1/2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Biliary Tract Cancer
Conditions
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
Trial Timeline
Mar 1, 2023 → Dec 30, 2024
NCT ID
NCT05742750About Camrelizumab and Apatinib Plus GP
Camrelizumab and Apatinib Plus GP is a phase 1/2 stage product being developed by Sun Pharmaceutical for Locally Advanced Biliary Tract Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05742750. Target conditions include Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced Biliary Tract Cancer were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
9
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05742750 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Locally Advanced Biliary Tract Cancer